Education
About Us
Working with TipRanks
Follow Us
Madrigal Pharmaceuticals Inc (MDGL)
NASDAQ:MDGL
MDGL Analyst Ratings
Strong Buy
14 Buy
0 Hold
1 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MDGL Stock 12 Month Forecast
Average Price Target
$413.87
▲(21.15% Upside)
| Highest Price Target$539.00 | Average Price Target$413.87 | Lowest Price Target$239.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TD Cowen
Reiterated
03/06/25
Leerink Partners
Reiterated
02/27/25
H.C. Wainwright
Reiterated
02/27/25
JMP Securities
Reiterated
02/27/25
B.Riley Financial
Upgraded
02/27/25
Canaccord Genuity
Reiterated
02/26/25
Bank of America Securities
Reiterated
02/26/25
Oppenheimer
Reiterated
02/26/25
Citi
Reiterated
02/26/25
Goldman Sachs
Reiterated
02/26/25
UBS
$441
Buy
29.09%
Upside
Reiterated
02/26/25
Madrigal Pharmaceuticals Phase 3 data 'encouraging,' says UBSMadrigal Pharmaceuticals Phase 3 data 'encouraging,' says UBS
Piper Sandler
$336→$400
Buy
17.09%
Upside
Reiterated
02/14/25
Madrigal Pharmaceuticals (MDGL) Receives a Buy from Piper Sandler
Evercore ISI
$392
Buy
14.75%
Upside
Reiterated
02/12/25
Madrigal Pharmaceuticals (MDGL) Gets a Buy from Evercore ISIWe continue to recommend owning MDGL into what we anticipate will be a strong 2025, despite net pricing headwinds from Medicare Part D Redesign (note here) & contracting. Our 2025 estimate is $646M or 368% y/y growth, which is above consensus of $514M. We continue to anticipate MASH to be a large market with an appetite for multiple treatment options and will revisit our 2026 assumptions, which assumes relatively stable patient adds through 2025-2026. Slides illustrating finding from the survey inside.
Clear Street
$386
Buy
12.99%
Upside
Initiated
01/30/25
Clear Street starts Madrigal Pharmaceuticals (MDGL) at Buy, bullish view on Rezdiffras launch and its revenue-generating potentialClear Street analyst Kaveri Pohlman initiates coverage on Madrigal Pharmaceuticals (NASDAQ: MDGL) with a Buy rating and a price target of $386.00.
Jefferies
$398
Buy
16.50%
Upside
Assigned
01/14/25
Madrigal Pharmaceuticals' Strong Market Position and Promising Outlook Drive Buy Rating
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TD Cowen
Reiterated
03/06/25
Leerink Partners
Reiterated
02/27/25
H.C. Wainwright
Reiterated
02/27/25
JMP Securities
Reiterated
02/27/25
B.Riley Financial
Upgraded
02/27/25
Canaccord Genuity
Reiterated
02/26/25
Bank of America Securities
Reiterated
02/26/25
Oppenheimer
Reiterated
02/26/25
Citi
Reiterated
02/26/25
Goldman Sachs
Reiterated
02/26/25
UBS
$441
Buy
29.09%
Upside
Reiterated
02/26/25
Madrigal Pharmaceuticals Phase 3 data 'encouraging,' says UBSMadrigal Pharmaceuticals Phase 3 data 'encouraging,' says UBS
Piper Sandler
$336→$400
Buy
17.09%
Upside
Reiterated
02/14/25
Madrigal Pharmaceuticals (MDGL) Receives a Buy from Piper Sandler
Evercore ISI
$392
Buy
14.75%
Upside
Reiterated
02/12/25
Madrigal Pharmaceuticals (MDGL) Gets a Buy from Evercore ISIWe continue to recommend owning MDGL into what we anticipate will be a strong 2025, despite net pricing headwinds from Medicare Part D Redesign (note here) & contracting. Our 2025 estimate is $646M or 368% y/y growth, which is above consensus of $514M. We continue to anticipate MASH to be a large market with an appetite for multiple treatment options and will revisit our 2026 assumptions, which assumes relatively stable patient adds through 2025-2026. Slides illustrating finding from the survey inside.
Clear Street
$386
Buy
12.99%
Upside
Initiated
01/30/25
Clear Street starts Madrigal Pharmaceuticals (MDGL) at Buy, bullish view on Rezdiffras launch and its revenue-generating potentialClear Street analyst Kaveri Pohlman initiates coverage on Madrigal Pharmaceuticals (NASDAQ: MDGL) with a Buy rating and a price target of $386.00.
Jefferies
$398
Buy
16.50%
Upside
Assigned
01/14/25
Madrigal Pharmaceuticals' Strong Market Position and Promising Outlook Drive Buy Rating
Best Analysts Covering Madrigal Pharmaceuticals
Which Analyst Should I Follow If I Want to Buy MDGL and Sell After:
1 Month
xxx
Success Rate
14/22 ratings generated profit
Average Return
+12.61%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 63.64% of your transactions generating a profit, with an average return of +12.61% per trade.
3 Months
xxx
Success Rate
12/14 ratings generated profit
Average Return
+16.95%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 85.71% of your transactions generating a profit, with an average return of +16.95% per trade.
1 Year
2 Years
xxx
Success Rate
22/22 ratings generated profit
Average Return
+118.54%
reiterated a xxx
rating 26 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +118.54% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MDGL Analyst Recommendation Trends
Rating
Nov 24
Dec 24
Jan 25
Feb 25
Mar 25
Strong Buy
16
8
1
2
2
Buy
9
9
21
25
25
Hold
4
3
5
2
2
Sell
3
2
3
3
3
Strong Sell
0
0
2
2
2
total
32
22
32
34
34
Each month's total comprises the sum of three months' worth of ratings.
MDGL Financial Forecast
MDGL Stock Forecast FAQ
What is MDGL’s average 12-month price target, according to analysts?
Based on analyst ratings, Madrigal Pharmaceuticals Inc’s 12-month average price target is $413.87.
What is MDGL’s upside potential, based on the analysts’ average price target?
Madrigal Pharmaceuticals Inc has 21.15% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MDGL a Buy, Sell or Hold?
Madrigal Pharmaceuticals Inc has a consensus rating of Strong Buy which is based on 14 buy ratings, 0 hold ratings and 1 sell ratings.
What is Madrigal Pharmaceuticals Inc’s price target?
The average price target for Madrigal Pharmaceuticals Inc is $413.87. This is based on 15 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $539.00 ,the lowest forecast is $239.00. The average price target represents 21.15% Increase from the current price of $341.62.
The highest analyst price target is $539.00 ,the lowest forecast is $239.00. The average price target represents 21.15% Increase from the current price of $341.62.
What do analysts say about Madrigal Pharmaceuticals Inc?
Madrigal Pharmaceuticals Inc’s analyst rating consensus is a Strong Buy. This is based on the ratings of 15 Wall Streets Analysts.
How can I buy shares of MDGL?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.